BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$1.97 USD
-0.05 (-2.24%)
Updated May 22, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
BioXcel Therapeutics, Inc. [BTAI]
Reports for Purchase
Showing records 61 - 80 ( 109 total )
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL701 Phase 2 Prostate Cancer Program Initiated; Catalysts Abound; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Progress Unimpeded Thus Far; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Pivotal Phase 3 Program Enrollment Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Pivotal Phase 3 Program Enrollment Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2019 Financial Results; SERENITY and TRANQUILITY Advancing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline in a Single Product Story Materializing; Raising PT to $95
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
RELEASE Trial Authorization Granted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Phase 1b/2 Trial Starts Enrollment; Reiterate Buy; Raising PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SERENITY Pivotal Program Initiates Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL701 Clinical Assessment Expansion Into Multiple Solid Tumor Types; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SERENITY Pivotal Program Gets FDA Green Light; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal BXCL501 Program Starting Soon; 3Q19 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Prostate Cancer Foundation Scientific Retreat Takeaways; Solid Financial Position; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Leveraging the Digital Age; BXCL501 Program Initiative With Wearable Digital Devices; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R